{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:39:33Z","timestamp":1787841573249,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    : Metastatic lung carcinoids (MLCs) represent a rare subset of lung cancers with distinct histologic subtypes. Survival outcomes and prognostic factors have not been well-studied in the real-world setting. This study investigates the impact of various treatments, including chemotherapy, hormonal therapy, and no treatment, on the overall survival (OS) of patients with typical and atypical MLC.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Patients with MLC between 2010 and 2020 were included from the National Cancer Database based on histologic codes ICD-O-3 8240\/3 and 8249\/3. Kaplan\u2013Meier curves and multivariate Cox proportional hazard regression were used to compare OS and evaluate prognostic factors.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The median age at diagnosis was 68 and 69 years for atypical and typical MLC, respectively. The 3-year OS for the atypical MLC cohort was 22.11%, and for typical MLC was 41.94% (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001). In the atypical MLC cohort, chemotherapy showed a nonsignificant benefit in OS (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.73\u20131.05;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u20090.21), whereas hormonal therapy was associated with significantly improved OS (HR, 0.72; 95% CI, 0.52\u20130.98;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.04). However, in the typical MLC cohort, chemotherapy was associated with adverse OS (HR, 2.15; 95% CI, 1.85\u20132.49;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.0001), and hormonal treatment showed better, albeit nonsignificant OS (HR, 0.84; 95% CI, 0.67\u20131.05;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u20090.13).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    There is a notable difference in survival outcomes between typical and atypical MLC based on the treatment strategies. While hormonal therapy shows improvement in the OS, the effectiveness of chemotherapy varies depending on the histologic subtype. These findings emphasize the necessity for personalized therapeutic approaches based on the specific characteristics of MLC, ultimately contributing to improved patient outcomes in this challenging oncologic group. Further research is warranted to validate and expand upon these observations.\n                  <\/jats:p>","DOI":"10.4103\/hemoncstem.hemoncstem-d-24-00001","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T02:00:14Z","timestamp":1745373614000},"page":"14-20","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Survival and Chemotherapy Response in Metastatic Lung Carcinoids: Insights from the National Cancer Database"],"prefix":"10.4103","volume":"18","author":[{"given":"Niraj","family":"Neupane","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet K.","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic Health System, Mankato, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham Moases","family":"Ghaffary","sequence":"additional","affiliation":[{"name":"Isfahan Neuroscience Research Center, Isfahan University School of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Houle","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Ghimire","sequence":"additional","affiliation":[{"name":"Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binita","family":"Neupane","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangharsha","family":"Thapa","sequence":"additional","affiliation":[{"name":"New York Medical College, Westchester Medical Center, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Mirmosayyeb","sequence":"additional","affiliation":[{"name":"Isfahan Neuroscience Research Center, Isfahan University School of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeni","family":"Kharel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengu","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utsav","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"R1-20250430","doi-asserted-by":"crossref","first-page":"vii65","DOI":"10.1093\/annonc\/mdq380","article-title":"Advances in neuroendocrine lung tumors","volume":"21","author":"Travis","year":"2010","journal-title":"Ann Oncol"},{"key":"R2-20250430","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2147\/OTT.S32464","article-title":"Focus on treatment of lung carcinoid tumor","volume":"6","author":"Noel-Savina","year":"2013","journal-title":"Onco Targets Ther"},{"key":"R3-20250430","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3390\/cancers13081753","article-title":"Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States","volume":"13","author":"Shah","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R4-20250430","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0000000000000419","article-title":"Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis","volume":"10","author":"Steuer","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R5-20250430","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/cancers10120510","article-title":"Management of typical and atypical pulmonary carcinoids based on different established guidelines","volume":"10","author":"Gosain","year":"2018","journal-title":"Cancers (Basel)"},{"key":"R6-20250430","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1634\/theoncologist.2014-0037","article-title":"Real-world study of everolimus in advanced progressive neuroendocrine tumors","volume":"19","author":"Panzuto","year":"2014","journal-title":"Oncologist"},{"key":"R7-20250430","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"R8-20250430","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"R9-20250430","doi-asserted-by":"crossref","first-page":"3","DOI":"10.6004\/jnccn.2007.0003","article-title":"The NCCN guideline for distress management: a case for making distress the sixth vital sign","volume":"5","author":"Holland","year":"2007","journal-title":"J Natl Compr Cancer Network"},{"key":"R10-20250430","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jtho.2019.02.002","article-title":"Characterization, prognosis, and treatment of patients with metastatic lung carcinoid tumors","volume":"14","author":"Robelin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R11-20250430"},{"key":"R12-20250430","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2019.03.022","article-title":"The role of adjuvant therapy for atypical bronchopulmonary carcinoids","volume":"131","author":"Wegner","year":"2019","journal-title":"Lung Cancer"},{"key":"R13-20250430","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000486282","article-title":"Real-world treatment patterns for lung neuroendocrine tumors: a claims database analysis","volume":"94","author":"Broder","year":"2018","journal-title":"Oncology"},{"key":"R14-20250430","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1634\/theoncologist.2018-0520","article-title":"Treatment patterns and clinical outcomes in advanced lung neuroendocrine tumors in real\u2010world settings: a multicenter retrospective chart review study","volume":"24","author":"Dasari","year":"2019","journal-title":"Oncologist"},{"key":"R15-20250430","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/JTO.0000000000000065","article-title":"Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report","volume":"9","author":"Forde","year":"2014","journal-title":"J Thoracic Oncol"},{"key":"R16-20250430","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00432-022-03970-x","article-title":"Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis","volume":"149","author":"Zhang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R17-20250430","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.athoracsur.2020.09.029","article-title":"A national study of surgically managed atypical pulmonary carcinoid tumors","volume":"112","author":"Walters","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"R18-20250430","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/MPA.0b013e3181ec1380","article-title":"NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)","volume":"39","author":"Phan","year":"2010","journal-title":"Pancreas"},{"key":"R19-20250430","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.21037\/jtd.2018.06.88","article-title":"Long-term outcomes and prognostic factors of patients with surgically treated pulmonary atypical carcinoid tumors: our institutional experience with 68 patients","volume":"10","author":"Song","year":"2018","journal-title":"J Thorac Dis"},{"key":"R20-20250430","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1148\/rg.261055057","article-title":"Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings","volume":"26","author":"Chong","year":"2006","journal-title":"Radiographics"},{"key":"R21-20250430","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/thoraxjnl-2020-216555","article-title":"International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK\u20132 Study","volume":"77","author":"Araghi","year":"2022","journal-title":"Thorax"},{"key":"R22-20250430","first-page":"59","article-title":"Stress and other environmental factors affecting fertility in men and women: overview","volume":"101","author":"Negro-Vilar","year":"1993","journal-title":"Environ Health Perspect"},{"key":"R23-20250430","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2217\/cer-2021-0205","article-title":"Sex-based differences in the outcomes of patients with lung carcinoids","volume":"11","author":"Abdel-Rahman","year":"2022","journal-title":"J Compar Effect Res"},{"key":"R24-20250430","doi-asserted-by":"crossref","first-page":"15330338211036528","DOI":"10.1177\/15330338211036528","article-title":"The cancers-specific survival of metastatic pulmonary carcinoids and sites of distant metastasis: a population-based study","volume":"20","author":"Zhang","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"R25-20250430","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0003-4975(94)00630-P","article-title":"Carcinoid tumors of the lung: do atypical features require aggressive management?","volume":"59","author":"Marty-An\u00e9","year":"1995","journal-title":"Ann Thorac Surg"},{"key":"R26-20250430","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1002\/cam4.1515","article-title":"Assessment of the prognostic factors in patients with pulmonary carcinoid tumor: a population\u2010based study","volume":"7","author":"Huang","year":"2018","journal-title":"Cancer Med"},{"key":"R27-20250430","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF03032399","article-title":"Genomics of lung cancer may change diagnosis, prognosis and therapy","volume":"11","author":"Kopper","year":"2005","journal-title":"Pathol Oncol Res"},{"key":"R28-20250430","doi-asserted-by":"crossref","first-page":"e0951","DOI":"10.1002\/rcr2.951","article-title":"Advanced atypical lung carcinoid tumour successfully treated with carboplatin, etoposide and atezolizumab: a case report","volume":"10","author":"Yamamoto","year":"2022","journal-title":"Respirol Case Rep"},{"key":"R29-20250430","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1078-0432.CCR-17-1921","article-title":"Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcomechemotherapy outcome in LCNEC is predicted by RB1 status","volume":"24","author":"Derks","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R30-20250430","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw122","article-title":"Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression","volume":"108","author":"Polley","year":"2016","journal-title":"JNCI: J Natl Cancer Inst"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-24-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:02:14Z","timestamp":1787839334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-24-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/hemoncstem.hemoncstem-d-24-00001","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2023-12-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}